Lidia Serova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lidia Serova has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Esther Louise Sabban
New York Medical College, Valhalla, USA
5 shared publications - Akira Nakashima
Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Japan
1 shared publication - Andrej Tillinger
Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
1 shared publication - Bistra B. Nankova
Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY, USA
1 shared publication Hannah Mulhall
Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY, USA
1 shared publicationLishay G. Alaluf
Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York, 1059
1 shared publication
Latest Publications
- 8 May 2023
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 35 (11) , e13279
Potential benefits of intranasal neuropeptide Y include sustained extinction of fear memory
Compelling evidence in animals and humans from a variety of approaches demonstrate that neuropeptide Y (NPY) in the brain can provide resilience to development of many stress‐elicited symptoms. Preclinical experiments demonstrated that delivery of NPY by intranasal infusion to rats shortly after single exposure to traumatic stress in the single prolonged stress (SPS) rodent model of post‐traumatic stress disorder (PTSD) can prevent development of many relevant behavioral alterations weeks later, including heightened anxiety and depressive‐like behavior. Here, we examined responses to intranasal NPY in the absence of stress to evaluate the safety profile. Rats were administered intranasal NPY (150 μg/rat) or equal volume of vehicle (distilled water), and 7 days later they were tested on the elevated plus maze (EPM) and forced swim test (FST). There was no significant difference in the number of entries or duration in the open or closed arms, or in their anxiety index. Defecation on the EPM and immobility on the FST, measures of anxiety and depressive‐like behavior respectively, were similar in both groups. To further characterize potential benefits of intranasal NPY, its effect on fear memory and extinction, important features of PTSD, were examined. Intranasal administration of NPY at the time of the traumatic stress had a profound effect on fear conditioning a week later. It prevented the SPS‐triggered impairment in the retention of extinguished behavior, both contextual and cued. The findings support the translation of non‐invasive intranasal NPY delivery to the brain for PTSD‐behaviors including impairments in sustained extinction of fear memories.
- 8 May 2023
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 35 (11) , e13279
Potential benefits of intranasal neuropeptide Y include sustained extinction of fear memory
Compelling evidence in animals and humans from a variety of approaches demonstrate that neuropeptide Y (NPY) in the brain can provide resilience to development of many stress‐elicited symptoms. Preclinical experiments demonstrated that delivery of NPY by intranasal infusion to rats shortly after single exposure to traumatic stress in the single prolonged stress (SPS) rodent model of post‐traumatic stress disorder (PTSD) can prevent development of many relevant behavioral alterations weeks later, including heightened anxiety and depressive‐like behavior. Here, we examined responses to intranasal NPY in the absence of stress to evaluate the safety profile. Rats were administered intranasal NPY (150 μg/rat) or equal volume of vehicle (distilled water), and 7 days later they were tested on the elevated plus maze (EPM) and forced swim test (FST). There was no significant difference in the number of entries or duration in the open or closed arms, or in their anxiety index. Defecation on the EPM and immobility on the FST, measures of anxiety and depressive‐like behavior respectively, were similar in both groups. To further characterize potential benefits of intranasal NPY, its effect on fear memory and extinction, important features of PTSD, were examined. Intranasal administration of NPY at the time of the traumatic stress had a profound effect on fear conditioning a week later. It prevented the SPS‐triggered impairment in the retention of extinguished behavior, both contextual and cued. The findings support the translation of non‐invasive intranasal NPY delivery to the brain for PTSD‐behaviors including impairments in sustained extinction of fear memories.
- Open Access
- 19 April 2017
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 11, 203
NPY1 Receptor Agonist Modulates Development of Depressive-Like Behavior and Gene Expression in Hypothalamus in SPS Rodent PTSD Model
Delivery of neuropeptide Y (NPY) to the brain by intranasal infusion soon after traumatic stress has shown therapeutic potential, and prevented development of many behavioral and neuroendocrine impairments in the single prolonged stress (SPS) animal model of PTSD. Therefore, we examined whether the Y1R preferring agonist [Leu31Pro34]NPY is sufficient to prevent development of SPS induced depressive-like behavioral changes, and hypothalamic gene expression as obtained with intranasal NPY intervention. Male Sprague-Dawely rats were given intranasal infusion of either NPY (150 µg/rat), a low (68 µg /rat) or high (132 µg/rat) dose of [Leu31Pro34]NPY or vehicle immediately following the last SPS stressor, left undisturbed for one week and then tested for depressive-like behavior together with naïve unstressed controls. Vehicle treated animals had elevated immobility forced swim test (FST) and reduced sucrose preference, which were not observed in animals given NPY or the higher dose of [Leu31Pro34]NPY. This dose of [Leu31Pro34]NPY, like NPY, also prevented the SPS-elicited induction of CRF mRNA in the mediobasal hypothalamus. However, [Leu31Pro34]NPY did not prevent, but rather enhanced, the SPS-triggered induction of GR and FKBP5 mRNA levels in the mediobasal hypothalamus. Thus, [Leu31Pro34]NPY may be as effective as NPY and displays therapeutic potential for preventing development of depressive-like behaviors and dysregulation of the CRF/HPA system in PTSD. However, due to its different effects compared to NPY on GR and FKBP5 a broader agonist, such as NPY, may be more desirable.
- 19 April 2017
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 11, 203
Open AccessNPY1 Receptor Agonist Modulates Development of Depressive-Like Behavior and Gene Expression in Hypothalamus in SPS Rodent PTSD Model
Delivery of neuropeptide Y (NPY) to the brain by intranasal infusion soon after traumatic stress has shown therapeutic potential, and prevented development of many behavioral and neuroendocrine impairments in the single prolonged stress (SPS) animal model of PTSD. Therefore, we examined whether the Y1R preferring agonist [Leu31Pro34]NPY is sufficient to prevent development of SPS induced depressive-like behavioral changes, and hypothalamic gene expression as obtained with intranasal NPY intervention. Male Sprague-Dawely rats were given intranasal infusion of either NPY (150 µg/rat), a low (68 µg /rat) or high (132 µg/rat) dose of [Leu31Pro34]NPY or vehicle immediately following the last SPS stressor, left undisturbed for one week and then tested for depressive-like behavior together with naïve unstressed controls. Vehicle treated animals had elevated immobility forced swim test (FST) and reduced sucrose preference, which were not observed in animals given NPY or the higher dose of [Leu31Pro34]NPY. This dose of [Leu31Pro34]NPY, like NPY, also prevented the SPS-elicited induction of CRF mRNA in the mediobasal hypothalamus. However, [Leu31Pro34]NPY did not prevent, but rather enhanced, the SPS-triggered induction of GR and FKBP5 mRNA levels in the mediobasal hypothalamus. Thus, [Leu31Pro34]NPY may be as effective as NPY and displays therapeutic potential for preventing development of depressive-like behaviors and dysregulation of the CRF/HPA system in PTSD. However, due to its different effects compared to NPY on GR and FKBP5 a broader agonist, such as NPY, may be more desirable.
- 1 January 2014
- Published by Elsevier
- p. 215-216
Neuropeptide Y Infusion to Rats Attenuates Development of PTSD-Like Symptoms to Traumatic Stress
- 1 January 2014
- Published by Elsevier
- p. 215-216
Neuropeptide Y Infusion to Rats Attenuates Development of PTSD-Like Symptoms to Traumatic Stress
- 6 December 2013
- Published by Elsevier
- p. 7-8
Estradiol-Mediated Regulation of Gene Expression of Catecholamine Biosynthetic Enzymes
- 6 December 2013
- Published by Elsevier
- p. 7-8
Estradiol-Mediated Regulation of Gene Expression of Catecholamine Biosynthetic Enzymes
- 1 January 2002
- Published by Springer Nature
- p. 321-324
Dynamics of Transcriptional Events in Stress-Triggered Regulation of Adrenal Catecholamine Biosynthetic Enzymes
- 1 January 2002
- Published by Springer Nature
- p. 321-324
Dynamics of Transcriptional Events in Stress-Triggered Regulation of Adrenal Catecholamine Biosynthetic Enzymes